Navigation Links
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Date:4/27/2009

ced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the rate of objective tumor response for the expansion stage of this trial will not be consistent with the objective tumor response experienced in the first stage of the trial and the risk that the standard carboplatin and paclitaxel response rate will not be improved as a result of the combination therapy. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could c
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
2. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
3. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
4. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
5. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
6. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
7. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
8. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
11. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
(Date:5/21/2013)... Minneapolis, MN (PRWEB) May 21, 2013 ... a patented automatic colony counter, announced today that they ... four products , the IncuCount, IntelliCount, InCount and ... price and sophistication are especially useful in food microbiology ... been given an updated look. A bright white ...
(Date:5/21/2013)... May 21, 2013 Possible mold re-infestation in ... according to a report from eagletribune.com posted May 14, 2013, ... case the result is positive, My Cleaning Products offered a ... chemical ingredients. , It was said in the Eagle Tribune ... in the campus sparked after a first-grade classroom was closed ...
(Date:5/21/2013)... Clinovo's new “CDISC Standards: Theory and ... on June 11th, 2013. The TechTrainings are technical hands-on ... next step in their professional career. The class will ... streamed online. , Taught by Sy Truong, President at ... Standards: Theory and Application” class will give an overview ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3Clinovo Launches TechTrainings on CDISC Standards 2
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... GeneLink Biosciences, Inc. (OTCBB: GNLK), a leading consumer ... the stock of its wholly owned direct-selling subsidiary ... (OTCBB: WELL), another public company operating in the ... and Capsalus executed definitive agreements for the sale ...
... 2012 Senior analysts from The Advisory Board Company,s ... Vegas preparing to provide an immediate analysis of the ... Management Systems Society,s HIMSS12 Annual Conference and Exhibition, which ... http://photos.prnewswire.com/prnh/20110802/PH45999LOGO ) By Monday, the ...
Cached Biology Technology:GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy 2Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy 3
(Date:5/18/2013)... presented today at Digestive Disease Week (DDW) explores new ... impact of coffee on autoimmune disease and palliative care ... has been associated with reduced risk of fibrosis, a ... of java each month also correlate with lower risk ... Mayo Clinic, Rochester, MN, linked coffee consumption with reduced ...
(Date:5/18/2013)... (May 18, 2013) An increasing number of ... interventions to resolve, according to research presented at ... study targeting obesity, researchers at the Cleveland Clinic ... unique pattern of exhaled breath compared to their ... organic compound levels that can be correlated to ...
(Date:5/17/2013)... the white noise of the South, but the night belongs ... air hangs heavy from the humidity and the sounds of ... species of frogs, toads and salamanders, is the center of ... swamps are the auditorium for their symphonic choruses, the scientists ... or ARMI, have front-row seats. , Amphibians, which ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... different gene mutations, but just how these mutations contribute to ... new clue comes from scientists at the University of North ... Their research indicates that early life sun exposure, from birth ... melanomas with BRAF gene mutations. A different mutation, on the ...
... were estimated to be living with Alzheimer’s disease in 2006, ... Hopkins Bloomberg School of Public Health. The researchers also concluded ... than 106 million by 2050. By that time, 43 percent ... to that of a nursing home. The findings were presented ...
... at x-rays of hands, searching out the telltale signs of ... arthritis. With these clinical features at his side, he turns ... genome – to figure out what makes these people susceptible ... finally closed the circle between key genes identified in his ...
Cached Biology News:Sun exposure early in life linked to specific skin cancer gene mutation 2Alzheimer's disease to quadruple worldwide by 2050 2Breakthrough developments in rheumatoid arthritis reported 2Breakthrough developments in rheumatoid arthritis reported 3Breakthrough developments in rheumatoid arthritis reported 4
Form: Ready to use Applications: ELISA...
Request Info...
Form: Concentrated Applications: ELISA...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
Biology Products: